Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 24 for “"Orphan Drugs"”.
-
Patent Rights & International Public Health: Orphan Drugs
… of research and investment into less common orphan diseases, resulted in a situation commonly referred to as orphan drugs: drugs targeting those diseases which have not yet been adopted by the pharmaceutical industry. Two main pieces of orphan drug legislation were introduced in the US and …
-
Orphan Drugs: Designations, Approvals, and Prices in the US
… dissertation assessed the characteristics of orphan drug designations and approvals and the factors associated with the time lag between orphan designation and approval in the US from 1983 to 2021. It also evaluated the treatment cost of orphan and non-orphan drugs and factors explaining the …
-
Value Assessment of Orphan Drugs and Treatments for Rare Diseases
OBJECTIVES: In 1983 the US Orphan Drug Act was passed to facilitate commercialization of drugs to treat rare diseases. The market value for orphan drugs in the US reached $90 billion annually in 2014, with worldwide sales forecast at $176 billion. Payers and policymakers need robust methodology for …
-
UTILIZATION CONTROLS FOR ORPHAN DRUGS: PRIOR AUTHORIZATION DOES NOT CORRELATE WITH LOWER DRUG USE
Background: While 7 of the top selling drugs in the U.S. have orphan status, 95% of 7000 rare diseases still lack treatments. With the growing number of expensive orphan drugs in the market, insurers have increasingly placed utilization controls (UCs), like prior authorization (PA), on orphan drugs …
-
Policies and Price Controls on the Research and Development of Orphan Drugs in the United States and the European Union
… aims to quantify the differences in US and EU orphan drug development. Orphan drugs are pharmaceutical products that treat rare diseases. Both the EU and US aim to stimulate orphan drug production with policies including national grants, tax credits, and extended periods of market exclusivity. …
-
Economic Aspects of Reimbursement of Drugs for Rare Diseases
The reimbursement of drugs that treat rare diseases, also known as orphan drugs, have been the topic of much debate in the last few years presenting a problem to decision makers who are challenged by increasing drug budgets. This thesis covers three main objectives: 1. Are the Incremental Cost …
-
Ethics in the service of the rare disease patient: Application of the thought of John Rawls and Paul Ramsey toward the increased availability of orphan drugs
… is a very small commercial market. Further, drugs for rare diseases are scrutinized by the Food and Drug Administration in the same manner as those for more common diseases--a contingency which, due to the enormous cost of drug research, further discourages profit-driven pharmaceutical …
-
Meta-analysis to Identify and Evaluate Factors Associated with Regulatory Approval of Orphan Drugs (OD) to Develop an Algorithm for Predicting Regulatory Approval (Success) and to Develop a Standardized Tool to Improve Orphan Drug Portfolio Decision-making
… probability of regulatory success (PRS) for new orphan drugs after phase II testing has been conductedwith the objective of providing a tool to improve drug portfolio decision-making.Methods: Examined 132 studies from recent publications (2005 onwards). Data on safety, efficacy, operational, …
-
Issues, Challenges and Opportunities for Economic Evaluation in Rare Diseases
Background and objectives Orphan drugs have surged in recent decades, but economic evaluation in rare diseases remains challenging. The main research aim set out to explore issues, challenges and opportunities for economic evaluation in rare disease. Methods A comprehensive umbrella review was …
-
Expensive drugs for rare diseases : an anthropological analysis of the cultural, political, and economic dimensions of metabolic disease
… potentially life-saving and/or life lengthening orphan drugs costing anywhere from $100,000.00 to $850,000.00 per patient per year is a complicated matter. This study is an anthropological examination of the debates surrounding ‘expensive drugs for rare diseases’, a term that has come to …
-
Addressing the Needs of Patients with Rare Diseases in Canada: An Evaluation of Orphan Drug Incentives
… is currently uncertain whether or not a Canadian orphan drug policy will be given further consideration any time in the near future, this thesis seeks to consider the potential impact that three different orphan drug incentives could be expected to have in Canada. Specifically, market exclusivity, …
-
Towards accessibility for Rare Diseases RD(s) therapies from an international to local perspective
… worldwide, yet fewer than 10% have access to orphan drugs (ODs). Variation in how RDs and ODs are defined across countries affects clinical recognition, policy development, research priorities, and access to treatment. In Saudi Arabia (SA), health system transformation under Vision 2030 has …
-
Custom affinity chromatography : development of a novel platform for rapid creation and validation of affinity media using DNA aptamer based ligands
… and operations needed to manufacture biologic drugs safely for the treatment of major diseases. Those technologies have enabled development of highly efficient and cost-effective platforms for downstream processing of monoclonal antibody (mAb) based drugs. But translating those advances to …
-
Maximising e-health initiatives to support the diagnosis and tracking of rare diseases
… Lastly, the thesis assesses the accessibility of orphan drugs, analyses regulatory challenges, and advocates for continued efforts to ensure patients receive necessary treatments. Collectively, these findings advocate for a unified strategy to address the complexities of rare diseases, leveraging …
-
Untersuchungen zur Störung der Proteinfaltung und zur stabilisierenden Wirkung niedermolekularer Verbindungen auf das Glutaryl-CoA-Dehydrogenase-Protein
… für die pharmazeutische Entwicklung eines orphan drugs für Kinder mit GA1 dar.
-
Suffering individuals and the sustainable collective : rare disease drug access and care in Canada
… and manage meaning around controversial costly ‘orphan’ drugs for rare genetic disease in Canada. Based on 18 months of multi-sited ethnographic fieldwork across Canada, I argue that practices around rare disease drug development and access have created two competing moral/ontological frames. …
-
Making the most of a few small population clinical trials
… by a randomized controlled trial. According to Orphanet, more than 1829 trials among 29 countries focus on more than 800 rare conditions. This number of historical and ongoing trials explains the urgent need for evaluating and developing tailor-made statistical methods for small populations and …
-
MOLECULAR DYNAMICS AND CHEMINFORMATICS METHODS TO EXPLORE THE CHEMICAL REALITY
… in particular in the evaluation process for orphan drugs (i.e., drugs for rare diseases). A new molecule needs to be dissimilar from any other existing drug for a given disease to be assigned the financially advantageous status of orphan drug. Currently, there are many ways to define whether …
-
Development and Licensing of Bio-Pharmaceuticals
… impact of the United States (US) government's orphan drug incentive scheme on pharmaceutical drug development. Biopharmaceuticals approved in the US and the EU over the last 10 years were searched within publicly accessible sources. These searches identified 147 biopharmaceuticals that were …
Page 1 of 2